Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The irritable bowel syndrome treatment market attained a value of USD 2.90 Billion in 2025 and is projected to expand at a CAGR of 10.10% through 2035. The market is further expected to achieve USD 7.59 Billion by 2035. Phenotype-specific prescribing is creating a commercially attractive pathway for differentiated therapies. With IBS affecting about 12% of Americans, treatment developers can target clinically defined populations rather than the broader gastrointestinal market. The expansion of pediatric indications and continued development of NHE3-based therapies also demonstrates how companies can extend product lifecycles by addressing underserved age groups, treatment sequences, and symptom combinations.
Key Market Trends and Insights
- Prescription demand is supported by established therapies, with the FDA’s 2025 expansion of Linzess to patients aged 7 years and older creating an additional treatment population. This broadens the commercial opportunity for constipation-focused IBS therapies beyond adult patients.
- The IBS-D segment is increasingly differentiated by mechanism-specific therapies. The FDA’s March 2025 approval of the first generic eluxadoline introduces additional competition to Viberzi, potentially reshaping prescribing and procurement dynamics for diarrhoea-predominant IBS treatment.
- Gastroenterology remains central to IBS treatment, with a U.S. study reporting that 45.3% of IBS-related physician visits were handled by gastroenterologists. The concentration of specialist care supports prescription-led treatment and continued demand for therapies targeting distinct IBS phenotypes, thus propelling the irritable bowel syndrome treatment market growth.
Market Size & Forecast
- Market Size in 2025: USD 2.90 Billion
- Projected Market Size in 2035: USD 7.59 Billion
- CAGR from 2026 to 2035: 10.10%
- Fastest-Growing Regional Market: North America
Pediatric treatment expansion is opening a previously narrower prescription opportunity. IIn November 2025, the U.S. FDA approved the use of Linzess for IBS-C in children 7 years and above, marking the first time an FDA approved drug is being used for the treatment of pediatric IBS-C. Pharmaceutical companies will thus be able to treat their patients through prescription therapy options. Growing demand for subtype-specific treatment is leading to product diversification that goes beyond just symptom treatment. IBS-C and IBS-D require different therapeutic approaches, supporting specialised products such as linaclotide for constipation-predominant IBS and rifaximin or eluxadoline for diarrhoea-predominant IBS. The availability of treatments designed around bowel-pattern differences enables companies to target defined patient groups and expand therapeutic adoption through more tailored treatment pathways, thereby boosting the irritable bowel syndrome treatment market value.
Innovation is moving toward live biotherapeutics, probiotics, postbiotics and faecal microbiota transplantation (FMT) that directly modify intestinal microbial activity. A 2025 landscape analysis identified 305 interventional clinical trials investigating gut-microbiota modulation therapies for IBS, with IBS-D accounting for 49.6% of trials. One example, MRx1234, a Blautia hydrogenotrophica-based live biotherapeutic, was evaluated in 366 IBS patients; responder rates were 25.0% versus 17.1% for placebo in IBS-C and 23.4% versus 17.8% in IBS-D. Another 2024 trial involving 200 IBS-D patients found significant symptom-severity reductions with Bifidobacterium longum ES1 and its heat-treated postbiotic versus placebo. These developments indicate increasing emphasis on microbiome-directed, subtype-specific treatment strategies.
It is still difficult to diagnose IBS since there is no validated biomarker for it. Therefore, it depends on a combination of symptoms and elimination of other possible disorders of the digestive tract. It is one of the reasons that may postpone starting treatment. This issue can be solved by the introduction of the Rome IV diagnostic criteria, development of the biomarker, and conducting the symptom-based test. Better differentiation of IBS-C, IBS-D and mixed presentations can also help physicians select appropriate therapies earlier and reduce unnecessary diagnostic procedures, supporting more efficient treatment pathways and improving patient access to targeted IBS medicines, thereby boosting the irritable bowel syndrome treatment market developments.
Compound Annual Growth Rate
10.1%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends and Recent Developments
Ironwood Pharmaceuticals initiated the STARS-2 Phase III trial in June 2026 to evaluate apraglutide in adults with short bowel syndrome with intestinal failure who depend on parenteral support. The company had previously aligned key trial-design elements with the U.S. FDA following discussions in late 2025. Although the programme targets a related gastrointestinal condition rather than IBS, the development strengthens Ironwood’s broader gastrointestinal therapeutics pipeline and demonstrates continued investment in specialised GI treatments.
Ironwood Pharmaceuticals announced in May 2026 that Grand Life Sciences (Beijing) Co., Ltd. became its partner for linaclotide in China, including Hong Kong and Macau, after AstraZeneca assigned its rights and obligations under the existing collaboration. LINZESS is marketed in China for adults with IBS-C. The change expands Ironwood’s commercial partnership network for linaclotide and supports continued access to an established IBS-C therapy within the Chinese gastrointestinal pharmaceutical market.
The U.S. FDA approved Linzess (linaclotide) for patients aged 7 years and older with IBS-C in November 2025, making it the first FDA-approved treatment specifically for pediatric IBS-C. The approval was supported by a 12-week randomized, double-blind clinical trial involving patients aged 7–17 years, alongside extrapolation of efficacy from adult studies. The expansion creates a dedicated prescription treatment option for children with IBS-C and broadens the addressable patient population for linaclotide.
The U.S. FDA listed Zydus Pharmaceuticals’ eluxadoline tablets as a first generic drug approval on 14 March 2025, referencing Viberzi tablets and their indication for adults with IBS-D. Eluxadoline is an orally administered therapy used to manage diarrhoea-predominant IBS symptoms. The generic approval introduces an additional pharmaceutical supplier into the U.S. IBS-D treatment landscape, potentially broadening product availability while increasing competition around an established prescription treatment, thus shaping the trends of the irritable bowel syndrome treatment market.
Pediatric label expansion is opening new treatment pathways
In May 2026, the FDA approved LINZESS for functional constipation in children aged two years and older, extending its previous pediatric availability to younger patients. The product remained the only FDA-approved prescription therapy for pediatric functional constipation at that time. Although functional constipation is distinct from IBS-C, the regulatory expansion demonstrates how established GI assets can generate additional commercial value through age-group expansion. For IBS treatment companies, pediatric clinical programs can therefore become an important lifecycle-management strategy, particularly where adult mechanisms have established safety and efficacy profiles.
Mechanism diversification is intensifying competition within IBS-C
Tenapanor offers a differentiated NHE3-inhibition approach compared with GC-C agonists such as linaclotide. In March 2026, Ardelyx published a post-hoc analysis reporting bowel-movement improvements from week two and meaningful abdominal symptom improvements within four to five weeks in adults with IBS-C. The company is simultaneously evaluating tenapanor in pediatric IBS-C populations. Such development programs encourage manufacturers to compete on mechanism, onset of symptom improvement, tolerability, and treatment persistence rather than relying solely on broad IBS positioning.
Real-world evidence is becoming increasingly important for commercial differentiation
Companies are moving beyond conventional registration studies to understand treatment patterns, healthcare-resource utilization, adherence, and symptom outcomes. Ardelyx presented research at Digestive Disease Week 2026 examining patient characteristics associated with IBS-C treatment changes and their relationship with GI-related healthcare-resource utilization. Such evidence can support payer discussions, physician education, patient-support programs, and positioning within treatment sequences. This makes real-world evidence increasingly relevant to the commercialization of prescription IBS therapies.
Pricing and access strategies are becoming part of lifecycle management
Ironwood announced in January 2026 that the LINZESS list price had been lowered in response to evolving healthcare dynamics and patient-access considerations, while maintaining its expectation for higher U.S. net sales. The company subsequently reported stronger-than-expected 2026 performance and raised its full-year LINZESS U.S. net-sales guidance to $1.15-$1.20 billion in August 2026. This illustrates how pricing architecture, rebate changes, prescription demand, and access strategy can materially influence commercial performance even after a product has been established in the market.
Clinical development is increasingly targeting adjacent GI populations to extend asset value.
Ardelyx initiated the ACCEL Phase 3 study of tenapanor for chronic idiopathic constipation in January 2026, with approximately 700 patients planned for enrollment and topline data expected in the second half of 2027. The strategy illustrates how companies can leverage an established IBS mechanism across neighboring bowel disorders. For manufacturers, this creates opportunities to broaden the commercial footprint of gastrointestinal assets while building evidence and physician familiarity around a particular mechanism.
Irritable Bowel Syndrome Treatment Industry Segmentation
The Expert Market Research’s report titled "Irritable Bowel Syndrome Treatment Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- IBS-C
- IBS-C Market
- Linzess/Constella
- Amitiza
- Others
- IBS-D
- Xifaxan
- Viberzi
- Others
Key Insight: IBS-C is gaining traction through established secretagogues, with Linzess/Constella benefiting from expanded patient eligibility. In November 2025, the FDA approved Linzess as the first prescription treatment for IBS-C in children aged 7 years and older. Linzess and Amitiza were approved for IBS-C in 2012 and 2008, respectively, while 2025 IQVIA data showed 6.9 million prescriptions across key IBS-C products, growing 11% year-on-year. In IBS-D, Xifaxan (rifaximin) and Viberzi (eluxadoline) are gaining traction through targeted treatment of diarrhoea-predominant symptoms. Xifaxan recorded an estimated US annual sale of $1.905 billion, while Viberzi generated $266 million, based on IQVIA FY2020 data. Their differentiated mechanisms and established clinical use continue to support adoption where symptom-specific treatment is required.
Market Breakup by Application
- Cardiology
- Urology and Nephrology
- Oncology
- Gastroenterology
- Others
Key Insight: Gastroenterology is expected to see stronger adoption as gastroenterologists increasingly manage IBS through subtype-specific therapies and long-term symptom control. Growing specialist consultations, improved diagnostic assessment, and treatment pathways integrating dietary, pharmacological, and microbiome-focused approaches can further support uptake. Cross-specialty collaboration may also expand awareness of IBS among patients presenting with overlapping gastrointestinal symptoms. Meanwhile, healthcare institutions are increasingly incorporating gastroenterology-led care into outpatient management, supporting prescription-based treatment and follow-up. As pharmaceutical companies develop therapies addressing constipation, diarrhoea, abdominal pain, and bloating through differentiated mechanisms, their use across specialist-led settings can broaden. This wider clinical engagement can strengthen treatment adoption and create opportunities for market expansion across the listed application areas.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Insight: North America is expected to maintain strong traction, supported by established IBS diagnosis and prescription-based treatment. IBS prevalence in North America has been estimated at 7.1% under Rome IV criteria, while the FDA expanded Linzess approval to children aged 7 years and older with IBS-C in 2025, widening the addressable treatment population. Europe continues to represent a significant treatment base, with IBS prevalence estimated at 7.1% under Rome IV criteria across North America, Europe, Australia and New Zealand, alongside established specialist-led gastrointestinal care. Asia Pacific is gaining traction as diagnosis and awareness improve; regional prevalence has been estimated at 9.6%, with Japan, China and South Korea showing considerable patient populations. Latin America presents substantial potential, with IBS prevalence estimated at 17.5%, while Middle East and Africa recorded approximately 5.5%, creating opportunities for greater diagnosis and treatment adoption as healthcare access expands, thus driving the demand in the irritable bowel syndrome treatment market.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Irritable Bowel Syndrome Treatment Market Share
By type, IBS-C is positioned to dominate due to its differentiated prescription landscape
IBS-C represents a major portion of the prescription-treatment opportunity because it has several differentiated pharmacological mechanisms and established branded products. LINZESS is FDA-indicated for IBS-C in adults and pediatric patients aged seven years and older. Ironwood reported that LINZESS had surpassed 5.7 million unique patients treated since launch by the end of 2025, demonstrating substantial accumulated treatment exposure. The availability of linaclotide, lubiprostone, and tenapanor provides physicians with multiple treatment mechanisms. Such developments will thus boost irritable bowel syndrome treatment market trends in the long run.
IBS-D provides growth opportunities around unmet needs associated with diarrhea, urgency, abdominal discomfort, and bloating. Current treatment approaches include rifaximin and other symptom-directed medicines, while Pfizer identifies antibiotics such as rifaximin among treatment options used for IBS-D. The segment can benefit from demand for therapies that deliver predictable symptom control without creating additional constipation-related complications. Future growth is likely to favor products supported by durable symptom-response data and clear positioning within treatment algorithms.
By application, gastroenterology dominates because IBS diagnosis and treatment remain GI-centered
Gastroenterology remains the dominant application as IBS generates substantial specialist-level healthcare utilisation and treatment demand. In a U.S. analysis, 45.3% of IBS-related physician visits were handled by gastroenterologists, while 89% of patients received medication, demonstrating the specialty’s direct connection with pharmacological treatment. More recent data from a 2024 U.S. claims analysis of 102,887 IBS patients found median annual IBS-specific healthcare spending of US$1,127 per patient, rising to US$2,222 for IBS-C, highlighting the treatment intensity within gastroenterology.
The others segment is gaining traction particularly through GI dietetics and integrated symptom management rather than broad multidisciplinary care. A survey of 279 American College of Gastroenterology providers found that 91% of clinicians with access to a GI dietitian agreed that such access improved IBS management, while 42% lacked access to a local GI dietitian. In England, 76% of NHS trusts provided gastroenterology dietetic services, with a median of 3.64 dietitians per 100,000 population, indicating an established but uneven service base. This gap creates scope for dietitian-led IBS programmes, nutritional counselling and structured patient-support services to expand alongside drug-based treatment.
Irritable Bowel Syndrome Treatment Market Regional Analysis
By region, North America dominates through mature diagnosis, reimbursement, and branded treatment access
North America is the principal commercial hub for IBS treatment because it combines substantial disease prevalence with established prescription pathways and active product lifecycle management. In the United States, NIDDK estimates IBS prevalence at approximately 12%, while current FDA labeling confirms established prescription indications for IBS-C therapies. Commercial activity remains strong: Ironwood reported LINZESS U.S. net sales of $282.3 million in Q2 2026 and raised its full-year 2026 guidance to $1.15-$1.20 billion. The region therefore offers pharmaceutical companies an environment where prescription demand, specialist engagement, payer access, and lifecycle extensions can operate together, thereby directly boosting the irritable bowel syndrome treatment market regional growth.
Europe remains a significant established market, supported by organized gastroenterology networks and clinical-guideline infrastructure. Asia Pacific is increasingly important for future expansion as research into disorders of gut-brain interaction becomes more geographically diverse. Latin America and the Middle East and Africa offer additional opportunities but require stronger market-access planning because diagnosis, specialist availability, reimbursement, and medicine affordability vary considerably between countries.
Competitive Landscape
Leading irritable bowel syndrome treatment market players are primarily aiming to develop more targeted, effective, and tolerable therapies that address the distinct needs of IBS-C, IBS-D, and other patient subgroups. Companies are focusing on therapies that provide sustained symptom relief, particularly for abdominal pain, constipation, diarrhoea, and bloating, while reducing treatment-related side effects. There is also growing interest in novel mechanisms involving gut motility, intestinal secretion, visceral sensitivity, and the gut microbiome. Expanding clinical evidence and pursuing additional indications are further priorities for established pharmaceutical companies.
irritable bowel syndrome treatment companies are aiming to strengthen market access through regulatory approvals, strategic partnerships, licensing agreements, and geographic expansion. They are also investing in patient-centric treatment approaches and improved disease awareness to encourage diagnosis and treatment adoption. The development of differentiated therapies, expansion of gastrointestinal portfolios, and exploration of personalised treatment approaches are expected to remain important areas of focus as competition intensifies across IBS treatment segments.
Ironwood Pharmaceuticals, Inc.
Established in 1998 and headquartered in Boston, Massachusetts, United States, Ironwood Pharmaceuticals focuses on gastrointestinal therapies. Its key IBS treatment offering is LINZESS® (linaclotide), a guanylate cyclase-C agonist approved for irritable bowel syndrome with constipation (IBS-C). The company developed and commercialises LINZESS, with regional partnerships supporting its availability in international markets. It is also marketed as CONSTELLA® in several countries, providing an established pharmacological option for patients experiencing constipation-predominant IBS.
Allergan
Established in 1948 and historically headquartered in Dublin, Ireland, Allergan developed important gastrointestinal treatments before becoming part of AbbVie. Its IBS treatment offerings included VIBERZI® (eluxadoline), an oral prescription therapy indicated for adults with irritable bowel syndrome with diarrhoea (IBS-D). Allergan also participated in the commercialisation of LINZESS® (linaclotide) for IBS-C through its collaboration with Ironwood Pharmaceuticals. VIBERZI received U.S. FDA approval in 2015, strengthening Allergan’s presence in the IBS-D treatment segment.
Astellas Pharma
Established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas is headquartered in Tokyo, Japan. The company’s IBS treatment offering includes linaclotide, developed and commercialised in collaboration with Ironwood Pharmaceuticals for the Japanese market. Linaclotide is a guanylate cyclase-C receptor agonist that increases intestinal fluid secretion and supports intestinal transit, making it suitable for IBS-C. Astellas has advanced the therapy through clinical development and regulatory activities to address constipation-predominant IBS in Japan.
Takeda Pharmaceutical Company Limited
Founded in 1781 and headquartered in Tokyo, Japan, Takeda has a long-standing presence in gastroenterology. Its IBS treatment portfolio has included AMITIZA® (lubiprostone), a chloride channel activator used for constipation-related gastrointestinal conditions, including IBS-C in approved markets. Lubiprostone increases intestinal fluid secretion and facilitates stool passage, addressing constipation symptoms associated with IBS-C. Takeda has commercialised AMITIZA across relevant markets, although product rights and commercial arrangements differ by geography, supporting its participation in the constipation-focused IBS treatment landscape.
Other key players in the irritable bowel syndrome treatment market include AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Synthetic Biologics, Inc., Salix Pharmaceuticals, Abbott Laboratories., Johnson & Johnson Services Inc., GlaxoSmithKline plc, Ono Pharmaceutical Co., Ltd., Pfizer Inc., LEXICON PHARMACEUTICALS, INC, Bausch Health, and Ardelyx, among others.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Features of the Irritable Bowel Syndrome Treatment Market Report
- Quantitative assessment of the Irritable Bowel Syndrome Treatment Market across major therapeutic segments.
- Detailed IBS-C and IBS-D analysis covering leading mechanisms and commercial treatment categories.
- Regional assessment covering North America, Europe, Asia Pacific, Latin America, and MEA.
- Competitive benchmarking of established pharmaceutical companies and emerging GI innovators.
- Analysis of 2026 regulatory, clinical, commercial, and lifecycle-management developments.
- Action-oriented insights for manufacturers, investors, distributors, and healthcare stakeholders.
Why Choose Expert Market Research?
- Structured analysis combining pharmaceutical, regulatory, clinical, and commercial market intelligence.
- Focused assessment of treatment-specific opportunities rather than broad gastrointestinal market commentary.
- Evidence-led insights supporting strategic planning, product positioning, and market-entry decisions.
- Comprehensive regional and competitive analysis designed for B2B decision-makers.
- Current 2026 developments incorporated to support forward-looking business strategy.
Call to Action
Explore the latest Irritable Bowel Syndrome Treatment Market trends {FORECAST_PERIOD_START}} and gain detailed insights into treatment segments, regional opportunities, competitive strategies, regulatory developments, and emerging therapeutic approaches. The Irritable Bowel Syndrome Treatment Market forecast 2026-2035 provides decision-makers with structured intelligence to assess market opportunities, product positioning, investment priorities, and expansion strategies. Download the sample report to understand the Irritable Bowel Syndrome Treatment Markets Market Size, competitive landscape, and future growth opportunities.
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
